高中性粒细胞-淋巴细胞比值与2019冠状病毒病患者的发病率及死亡率升高相关
该研究为对前瞻性收集数据的回顾性分析,纳入2020年3月15日至2020年12月30日期间一家大型医疗中心内科ICU连续收治的2071例实验室确诊SARS-CoV-2感染患者,按入院时中性粒细胞-淋巴细胞比值中位数7.45分为高比值组和低比值组。结果发现,比值>7.45与机械通气需求增加(45.8% vs 38.0%,p<0.0001)、升压药治疗增加(55.6% vs 48.2%,p=0.001)及180天生存率降低(54.8% vs 67.0%,p<0.0001)相关;高比值组死亡风险为低比值组的1.32倍(95%CI 1.14-1.54)。作者认为入院时中性粒细胞-淋巴细胞比值是发病率和死亡率的独立危险因素,可能帮助临床医生识别高危患者并调整治疗。
要点
- 入院时中性粒细胞-淋巴细胞比值>7.45与机械通气需求增加相关(45.8% vs 38.0%,p<0.0001)。
- 入院时中性粒细胞-淋巴细胞比值>7.45与升压药治疗需求增加相关(55.6% vs 48.2%,p=0.001)。
- 入院时中性粒细胞-淋巴细胞比值>7.45与180天生存率降低相关(54.8% vs 67.0%,p<0.0001)。
- 高比值组死亡风险为低比值组的1.32倍(95%CI 1.14-1.54)。
- 作者认为入院时中性粒细胞-淋巴细胞比值是发病率和死亡率的独立危险因素,可能帮助识别高危患者并调整治疗。
适用人群与场景
- 2020年3月15日至2020年12月30日期间一家大型医疗中心内科ICU连续收治的2071例实验室确诊SARS-CoV-2感染患者。
诊断标准与关键阈值
- 按入院时中性粒细胞-淋巴细胞比值中位数7.45分为高比值组(>7.45)和低比值组(≤7.45)。
研究设计与关键结果
- 研究设计:对前瞻性收集数据的回顾性分析,单家大型医疗中心内科ICU,纳入2071例连续患者。
- 干预:入院时完成全血细胞计数及分类。
- 主要结果:中性粒细胞-淋巴细胞比值>7.45与机械通气需求增加相关(45.8% vs 38.0%,p<0.0001)、升压药治疗增加相关(55.6% vs 48.2%,p=0.001)、180天生存率降低相关(54.8% vs 67.0%,p<0.0001)。
- 高比值组死亡风险为低比值组的1.32倍(95%CI 1.14-1.54)。
证据类型、等级与局限
- 证据类型:对前瞻性收集数据的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为入院时中性粒细胞-淋巴细胞比值是发病率和死亡率的独立危险因素,该预后指标可能帮助临床医生适当识别疾病严重病程高风险患者并据此调整治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The neutrophil-lymphocyte ratio is an inexpensive and simple inflammatory marker. A higher ratio, indicative of an acute hyperinflammatory response or diminished overall physiologic health status, has been associated with poor prognoses. This study aimed to evaluate the prognostic potential of admission neutrophil-lymphocyte ratio in patients admitted to the medical ICU with coronavirus disease 2019.
DESIGN: Retrospective review of prospectively collected data.
SETTING: Medical ICU from a large medical center.
PATIENTS: 2,071 consecutive patients admitted to the medical ICU with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 between March 15, 2020, and December 30, 2020, were grouped by neutrophil-lymphocyte ratio above or below the median (7.45) at the time of hospital admission.
INTERVENTIONS: Complete blood count with differential at the time of hospital admission.
MEASUREMENTS AND MAIN RESULTS: A neutrophil-lymphocyte ratio above 7.45 at the time of hospital admission was associated with increased need for mechanical ventilation (45.8% vs 38.0%, p < 0.0001), vasopressor therapy (55.6% vs 48.2%, p = 0.001), and decreased survival through 180 days (54.8% vs 67.0%, p < 0.0001). Patients with a high neutrophil-lymphocyte ratio exhibited a 1.32 (95% CI, 1.14-1.54) times greater risk of mortality than those with a low neutrophil-lymphocyte ratio.
CONCLUSIONS: The neutrophil-lymphocyte ratio at the time of hospital admission is an independent risk factor for morbidity and mortality. This prognostic indicator may assist clinicians appropriately identify patients at heightened risk for a severe disease course and tailor treatment accordingly.
参考来源
- King AH, Mehkri O, Rajendram P, et al. A High Neutrophil-Lymphocyte Ratio Is Associated With Increased Morbidity and Mortality in Patients With Coronavirus Disease 2019. Crit Care Explor. 2021. PMID: 34036280. doi:10.1097/CCE.0000000000000444
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。